SALT LAKE CITY, March 12, 2009 (GLOBE NEWSWIRE) -- BSD Medical Corp. (Nasdaq:BSDM) announced today that Professor Rolf Issels, M.D. Ph.D. of the Munich University Medical School in Germany delivered an invited lecture entitled, "Regional Hyperthermia Combination with Chemotherapy for High Risk Soft Tissue Sarcoma" at The Society of Surgical Oncology conference recently concluded at the Phoenix Convention Center in Arizona. Dr. Issels, as the lead investigator for this major study, presented the results of a 341 patient randomized Phase III clinical trial that evaluated the benefit of adding hyperthermia therapy to chemotherapy for the treatment of cancer. The study was conducted at nine major European cancer treatment institutions and at Duke University Medical Center in the USA. The study demonstrated that both disease-free survival time and local tumor progression free survival time nearly doubled for patients with locally advanced, high-grade soft tissue sarcomas when hyperthermia therapy, using the BSD-2000 hyperthermia system, was added to chemotherapy, as compared to patients who received chemotherapy alone.
